CML CD34+ cells were treated with RITA, CPI-203, the combination thereof and nilotinib.. Treatment of CML cells with RITA, CPI-203, the combination thereof and nilotinib.
收藏NIAID Data Ecosystem2026-03-09 收录
下载链接：
https://www.ncbi.nlm.nih.gov/bioproject/PRJEB9942
下载链接
链接失效反馈官方服务：
资源简介：
To identify the molecular effects of combining the p53 activator RITA and MYC inhibitor CPI-203, we treated CML CD34+ cells with RITA, CPI-203, the combination thereof and nilotinib.
创建时间：
2016-05-25
